Agios Pharmaceuticals, Inc. (FRA:8AP)

Market Cap	1.35B -27.0%
Revenue (ttm)	38.18M +36.3%
Net Income	-342.00M
EPS	-5.93
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	22.80
Previous Close	23.60
Day's Range	22.80 - 22.80
52-Week Range	19.70 - 38.80
Beta	n/a
RSI	43.53
Earnings Date	Feb 12, 2026

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 488
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AP

Financial Performance

Financial numbers in USD